Aspen

Aspen Close to Covid Vaccine License Deal with J&J

South Africa's Aspen Pharmacare aims to ramp up its Covid-19 vaccine manufacturing capacity to 1.3 billion doses per year by February 2024, from 250 to 300 million doses at present, the company has said.

News

Mylan Buys Aspen’s European Thrombosis Assets

Mylan has agreed to buy the related intellectual property and commercialization rights of Aspen Pharmacare’s European thrombosis business for €641.9 million. The company will use proceeds from the sale to pay down debt.

News

GlaxoSmithKline Sells Australian Drugs to Aspen for $270 Million

Top-Feature

Citrine

Operationalizing AI in Polymer Development: How Syensqo Is Scaling Impact with the Citrine Platform

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

Aenova Holding GmbH

Mastering Modified Release: The Pellet-Based Approach

Global Impact Coalition (GIC)

Siemens Joins the Global Impact Coalition

Article

Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.